

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Sheet 1 of 3

Application No.	10/765,773
Filing Date	January 26, 2004
First Named Inventor	Hrair Kirakossian
Art Unit	1641
Examiner Name	Pensee T. Do
Attorney Docket Number	25237-12891

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No. Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-7,135,300	11-14-2006	Chan-Hui et al.
	A2	US-7,105,308	09-12-2006	Chan-Hui et al.
	A3	US-6,770,439	08-03-2004	Singh et al.
	A4	US-6,649,351	11-18-2003	Matray et al.
	A5	US-6,331,530	12-18-2001	Breslow et al.
	A6	US-5,994,069	11-30-1999	Hall et al.
	A7	US-2004/0229380 A1	11-18-2004	Chan-Hui et al.
	A8	US-2002/045178 A1	04-18-2002	Cantor et al.
	A9	US-2002/098478 A1	07-25-2002	Wold
	A10	US-2001/049105 A1	12-06-2001	Singh et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
	B1	DE 4307736 A1	09-23-1993	Olympus Optical Co., Ltd.	
	B2	WO 02/097112 A2	12-05-2002	Aclara Biosciences, Inc.	
	B3	WO 02/083954 A1	10-24-2002	PE Corp (NY)	
	B4	WO 02/29109 A2	04-11-2002	Aclara Biosciences, Inc.	
	B5	WO 00/16087 A1	03-23-2000	The Perkin-Elmer Corporation	
	B6	WO 97/17467 A1	05-15-1997	Pharmacia Biotech AB	

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C1	AUTIERO et al., "Role of PIGF in the Intra- and Intermolecular Cross Talk Between VEGF Receptors Flt1 and Flk1," Nature Medicine, June 8, 2003, pp. 936-943, Vol. 9.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application No.	10/765,773
Filing Date	January 26, 2004
First Named Inventor	Hrair Kirakossian
Art Unit	1641
Examiner Name	Pensee T. Do
Attorney Docket Number	25237-12891

Sheet 2 of 3

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C2	BURMER, G.C. et al., "Frequency and Spectrum of c-Ki-ras Mutations in Human Sporadic Colon Carcinoma, Carinomas Arising in Ulcerative Colitis, and Pancreatic Adenocarcinoma, Environmental Health Perspectives, 1991, pp. 27-31, Vol. 93.	
	C3	BUSKEN, C. et al., "Adenocarcinomas of the Gastro-Esophageal Junction: A Comparative Study of the Gastric Cardia and the Esophagus with Respect to Cyclooxygenase-2 Expression," Digestive Disease Week Abstracts and Itinerary Planner, 2003, Abstract No. 850.	
	C4	DREXLER, H.G. et al., "Recent Results on the Biology of Hodgkin and Reed-Sternberg Cells, II. Continuous Cell Lines," Leukemia and Lymphoma, 1993, pp. 1-25, Vol. 9.	
	C5	EMBLETON, M.J. et al., "Monoclonal Antibodies to Osteogenic Sacroma Antigens," Immunol. Ser., 1984, pp. 181-207, Vol. 23.	
	C6	European Supplementary Search Report, European Application EP 03815205.4, January 10, 2008, 6 pages.	
	C7	European Supplementary Search Report, European Application EP03746104.3, June 1, 2007, 2 pages.	
	C8	HSU, T.C., "Karyology of Cells in Culture," Tissue Culture Methods and Applications, Kruse and Patterson, Eds., Academic Press, N.Y., 1973, p. 764.	
	C9	KUNKEL, P. et al., "Expression and Localization of Scatter Factor/ Hepatocyte Growth Factor in Human Astrocytomas," Neuro-Oncology, April 2001, pp. 82-88, Vol. 3, No. 2.	
	C10	MONTESANO, R. et al., "Genetic Alterations in Esophageal Cancer and Their Relevance to Etiology and Pathogenesis: A Review," Intl. J. Cancer, 1996, pp. 225-235, Vol. 69, No. 3.	
	C11	SLAMON, D.J. et al., "Human Breast Cancer: Correlation of Relapse and Survival and Amplification of the HER-2/ <i>neu</i> Oncogene," Science, January 9, 1987, pp. 177-182, Vol. 235.	
	C12	TIAN, J. et al., "The Expression of Native and Cultured RPE Grown on Difference Matrices," Physiol. Genomics, February 24, 2004, pp. 170-182, Vol. 17.	
	C13	TOCKMAN, M.S. et al., "Considerations in Bringing a Cancer Biomarker to Clinical Application," Cancer Research, May 1, 1992, pp. 2711s-2718s, Vol. 52.	
	C14	VAN DYKE, D. et al., "Monosomy 21 in Hematologic Diseases," Cancer Genetics and Cytogenetics, 2003, pp. 137-141, Vol. 241.	
	C15	WATHELET, M. et al., "Electropherogram Comparison by Computer," Chemometrics and Intelligent Laboratory Systems, 1998, pp. 327-339, Vol. 4.	
	C16	WHITAKER, G.B. et al., "Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF ₁₆₅ and VEGF ₁₂₁ ," The Journal of Biological Chemistry, July 6, 2001, pp. 25520-25531, Vol. 276.	
	C17	WILDI, S. et al., "Overexpression of Activin A in Stage IV Colorectal Cancer," Gut Online, September 2001,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***Complete if Known*

Application No.	10/765,773
Filing Date	January 26, 2004
First Named Inventor	Hrair Kirakossian
Art Unit	1641
Examiner Name	Pensee T. Do
Attorney Docket Number	25237-12891

Sheet 3 of 3

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
		pp. 409-471, Vol. 49.	
	C18	ZASLAV, A.L. et al., "Significance of a Prenatally Diagnosed del(10)(q23)," American Journal of Medical Genetics, 2002, pp. 174-176, Vol. 107.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.